NA
D'Angelo, S., Tirri, E., Giardino, A.M., De Rosa, T., Matucci‐Cerinic, M., Dagna, L., et al. (2024). Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 27(3) [10.1111/1756-185x.15091].
Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study
D'Angelo, Salvatore;Ciccia, Francesco;Guggino, Giuliana;
2024-03-01
Abstract
NA
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Int J of Rheum Dis - 2024 - D_Angelo - Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNF drug.pdf
accesso aperto
Descrizione: letter
Tipologia:
Versione Editoriale
Dimensione
871.1 kB
Formato
Adobe PDF
|
871.1 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
